North America Diverticular Treatment Market

North America Diverticular Treatment Market (Type: Diverticulosis, Diverticulitis, and Diverticular Hemorrhage) - Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

North America Diverticular Treatment Market Outlook 2031

  • The industry in the region was valued at US$ 986.6 Mn in 2022
  • It is projected to grow at a CAGR of 7.6% from 2023 to 2031 and reach more than US$ 1.9 Bn by 2031

Analysts’ Viewpoint

Surge in prevalence of diverticular diseases, rise in healthcare expenditure, and increase in awareness about the disease are driving North America diverticular treatment market demand. Surge in geriatric population in the region is another factor propelling market progress. Sedentary lifestyle, consumption of diet having low fiber, and intake of high processed foods are expected to bolster North America diverticular treatment market value.

Increase in investment in development of advanced treatment options is projected to offer lucrative opportunities to market players. Post the COVID-19 pandemic, diverticular treatment companies are making data-driven decisions before investing in new products. They are investing significantly in the research and development of advanced diverticular treatment options.

North America Diverticular Treatment Market

North America Diverticular Treatment Market Synopsis

Diverticula are small, bulging pouches that can develop in the lining of the digestive tract, most commonly in the large intestine (colon). When these pouches become inflamed or infected, the condition is known as diverticulitis.

Diverticular treatment refers to the management and medical interventions used to address diverticulitis and its associated symptoms.

Prevalence of diverticular disease has been increasing in North America, posing a significant healthcare challenge. The disease is typically associated with age, and its prevalence tends to increase with advancing age.

According to an article published in the Gastroenterology Journal, more than 50% of Americans older than 60 years of age have diverticulosis, and diverticulitis is highly prevalent.

According to the National Institutes of Health (NIH), the prevalence of diverticular disease reaches as high as 65% by 85 years of age and estimated to be as low as 5% in those 40 years of age or younger in the U.S. Diverticulosis is quite common, especially as people age.

More than 30% of the U.S. adults between the ages of 50 and 59 and more than 70% of those older than 80 years have diverticulosis. Less than 5% of people with diverticulosis develop diverticulitis. In the U.S., about 200,000 people are hospitalized for diverticulitis and about 71,000 people for diverticular bleeding each year.

Rise in life expectancy across the world is increasing the number of elderly individuals. Older people are at higher risk of having diverticular disease, with studies showing that more than half of individuals over the age of 60 have diverticula in their colon.

Changes in dietary habits and lifestyle factors also play a major role in rise in prevalence of diverticular disease. A diet low in fiber and high in processed foods, combined with sedentary lifestyles, could contribute to constipation and increased pressure in the colon, leading to the formation of diverticula.

Obesity has become a major health concern in the region. It is linked to an increased risk of diverticular disease. Excess weight puts additional pressure on the colon, which can contribute to the development of diverticula. These factors are fueling market expansion in the region.

Increase in Incidence Driving Diverticulitis Segment

In terms of type, the diverticulitis segment accounted for largest North America diverticular treatment market share in 2022. The trend is expected to continue during the forecast period. Incidence of diverticulitis tends to increase with age, and it is more common in individuals over the age of 50. According to the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), approximately 200,000 cases of acute diverticulitis occur in the U.S. annually.

High Demand for Antibiotics and Anti-inflammatory Drugs

Based on treatment, the medication segment dominated the diverticular treatment market in North America in 2022. This is ascribed to high demand for diverticular bleeding and diverticulitis treatment antibiotics and anti-inflammatory drugs, which are the most common complications of the diverticular disease.

According to NIDDK, diverticulitis and diverticular bleeding occur in 10% to 25% and up to 15% of people with diverticulosis, respectively. This could require hospitalization and medical interventions. These factors are driving the medication segment.

Increase in Preference for Non-invasive Treatment Options

In terms of route of administration, the oral segment accounted for major market share in 2022. The trend is likely to continue during the forecast period due to ease of administration, high patient compliance, and availability of a range of oral drugs for the treatment of diverticular disease.

Rise in preference for non-invasive treatment options and high demand for antibiotics and anti-inflammatory drugs are expected to bolster the oral segment.

Widespread Availability of Retail Pharmacies

Based on distribution channel, the retail pharmacies segment dominated the market in North America in 2022. This can be ascribed to widespread presence of retail pharmacies. Convenience of retail pharmacies is also a key factor propelling the segment, as patients can easily buy medicine for diverticulitis from retail pharmacies, especially in rural areas where online and hospital pharmacies may be less accessible.

Retail pharmacies also offer personalized and timely services, including counseling, prescription filling, and medication management, which enhance patient satisfaction and loyalty.

North America Diverticular Treatment Market Analysis

According to North America diverticular treatment industry research report, the U.S. accounted for significant share of the regional market in 2022. This can be ascribed to large patient population in the U.S., high prevalence of diverticular disease, availability & adoption of advanced medical treatments on a large scale, and high healthcare spending.

The U.S. also has a well-established pharmaceutical industry, which is influencing the market statistics in the country.

Analysis of Key Players

The North America diverticular treatment market report concludes with the company profiles section that includes key information about the major players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace. They consider developing new treatments for diverticulitis to strengthen market position.

Major North America diverticular treatment market leaders are Pfizer, Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Mallinckrodt Pharmaceuticals, Abbott Laboratories, and GSK plc.

Key Developments in North America Diverticular Treatment Market

  • In January 2022, the American College of Physicians (ACP) released two new clinical guidelines for the treatment and diagnosis of diverticulitis. These guidelines highlight that the majority of patients with uncomplicated diverticulitis can be effectively treated in outpatient settings. Additionally, it is suggested that some patients may not require immediate antibiotic treatment.

Prominent players have been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

North America Diverticular Treatment Market Snapshot

Attribute Detail

Size in 2022

US$ 986.6 Mn

Forecast (Value) in 2031

More than US$ 1.9 Bn

Growth Rate (CAGR)

7.6%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment as well as country-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Type
    • Diverticulosis
    • Diverticulitis
    • Diverticular Hemorrhage
  • Treatment
    • Medication
      • Pain Reliever
      • Antibiotics
        • Amebicides
        • Sulfonamides
        • Quinolones and Fluoroquinolones
        • Lincomycin Derivatives
        • Miscellaneous Antibiotics
      • Anticholinergics / Antispasmodics
    • Nutritional Supplements
    • Probiotics
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Countries Covered

  • U.S.
  • Canada

Companies Profiled

  • Pfizer, Inc.
  • Novartis AG
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Abbott Laboratories
  • GSK plc

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was North America diverticular treatment market in 2022?

The industry in the region was valued at US$ 986.6 Mn in 2022

How big is North America diverticular treatment industry expected to be in 2031?

It is projected to reach more than US$ 1.9 Bn by 2031

What is estimated to be the CAGR of North America diverticular treatment market during the forecast period?

The market in the region is anticipated to expand at a CAGR of 7.6% from 2023 to 2031

Which is the prominent factor driving diverticular treatment in North America?

Rise in geriatric population is driving the market in the region.

Which country is likely to account for major share of North America diverticular treatment industry during the forecast period?

The U.S. is expected to account for largest market share

Who are the prominent players in North America diverticular treatment business?

Pfizer, Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Mallinckrodt Pharmaceuticals, Abbott Laboratories, and GSK plc

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: North America Diverticular Treatment Market

    4. Market Overview

        4.1. Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. North America Diverticular Treatment Market Value Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate

        5.2. Pipeline Analysis

        5.3. COVID-19 Impact Analysis

    6. North America Diverticular Treatment Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Type, 2017-2031

            6.3.1. Diverticulosis

            6.3.2. Diverticulitis

            6.3.3. Diverticular Hemorrhage

        6.4. Market Attractiveness Analysis, by Type

    7. North America Diverticular Treatment Market Analysis and Forecast, by Treatment

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Treatment, 2017-2031

            7.3.1. Medication

                7.3.1.1. Pain Reliever

                7.3.1.2. Antibiotics

                    7.3.1.2.1. Amebicides

                    7.3.1.2.2. Sulfonamides

                    7.3.1.2.3. Quinolones and Fluoroquinolones

                    7.3.1.2.4. Lincomycin Derivatives

                    7.3.1.2.5. Miscellaneous Antibiotics

                7.3.1.3. Anticholinergics/Antispasmodics

            7.3.2. Nutritional Supplements

            7.3.3. Probiotics

        7.4. Market Attractiveness Analysis, by Treatment

    8. North America Diverticular Treatment Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Route of Administration, 2017-2031

            8.3.1. Oral

            8.3.2. Parenteral

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. North America Diverticular Treatment Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by Distribution Channel, 2017-2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Attractiveness Analysis, by Distribution Channel

    10. North America Diverticular Treatment Market Analysis and Forecast, by Country

        10.1. Key Findings

        10.2. Market Value Forecast, by Country

            10.2.1. U.S.

            10.2.2. Canada

        10.3. Market Attractiveness Analysis, by Country

    11. U.S. Diverticular Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017-2031

            11.2.1. Diverticulosis

            11.2.2. Diverticulitis

            11.2.3. Diverticular Hemorrhage

        11.3. Market Value Forecast, by Treatment, 2017-2031

            11.3.1. Medication

                11.3.1.1. Pain Reliever

                11.3.1.2. Antibiotics

                    11.3.1.2.1. Amebicides

                    11.3.1.2.2. Sulfonamides

                    11.3.1.2.3. Quinolones and Fluoroquinolones

                    11.3.1.2.4. Lincomycin Derivatives

                    11.3.1.2.5. Miscellaneous Antibiotics

                11.3.1.3. Anticholinergics/Antispasmodics

            11.3.2. Nutritional Supplements

            11.3.3. Probiotics

        11.4. Market Value Forecast, by Route of Administration, 2017-2031

            11.4.1. Oral

            11.4.2. Parenteral

        11.5. Market Value Forecast, by Distribution Channel, 2017-2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Attractiveness Analysis

            11.6.1. By Type

            11.6.2. By Treatment

            11.6.3. By Route of Administration

            11.6.4. By Distribution Channel

    12. Canada Diverticular Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017-2031

            12.2.1. Diverticulosis

            12.2.2. Diverticulitis

            12.2.3. Diverticular Hemorrhage

        12.3. Market Value Forecast, by Treatment, 2017-2031

            12.3.1. Medication

                12.3.1.1. Pain Reliever

                12.3.1.2. Antibiotics

                    12.3.1.2.1. Amebicides

                    12.3.1.2.2. Sulfonamides

                    12.3.1.2.3. Quinolones and Fluoroquinolones

                    12.3.1.2.4. Lincomycin Derivatives

                    12.3.1.2.5. Miscellaneous Antibiotics

                12.3.1.3. Anticholinergics/Antispasmodics

            12.3.2. Nutritional Supplements

            12.3.3. Probiotics

        12.4. Market Value Forecast, by Route of Administration, 2017-2031

            12.4.1. Oral

            12.4.2. Parenteral

        12.5. Market Value Forecast, by Distribution Channel, 2017-2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Attractiveness Analysis

            12.6.1. By Type

            12.6.2. By Treatment

            12.6.3. By Route of Administration

            12.6.4. By Distribution Channel

    13. Competition Landscape

        13.1. Market Player - Competition Matrix (by tier and size of companies)

        13.2. Market Share Analysis, by Company, 2022

        13.3. Company Profiles

            13.3.1. Pfizer, Inc.

                13.3.1.1. Company Overview

                13.3.1.2. Product Portfolio

                13.3.1.3. SWOT Analysis

                13.3.1.4. Strategic Overview

            13.3.2. Novartis AG

                13.3.2.1. Company Overview

                13.3.2.2. Product Portfolio

                13.3.2.3. SWOT Analysis

                13.3.2.4. Strategic Overview

            13.3.3. Bayer AG

                13.3.3.1. Company Overview

                13.3.3.2. Product Portfolio

                13.3.3.3. SWOT Analysis

                13.3.3.4. Strategic Overview

            13.3.4. F. Hoffmann-La Roche Ltd.

                13.3.4.1. Company Overview

                13.3.4.2. Product Portfolio

                13.3.4.3. SWOT Analysis

                13.3.4.4. Strategic Overview

            13.3.5. Teva Pharmaceutical Industries Ltd

                13.3.5.1. Company Overview

                13.3.5.2. Product Portfolio

                13.3.5.3. SWOT Analysis

                13.3.5.4. Strategic Overview

            13.3.6. Sun Pharmaceutical Industries Ltd.

                13.3.6.1. Company Overview

                13.3.6.2. Product Portfolio

                13.3.6.3. SWOT Analysis

                13.3.6.4. Strategic Overview

            13.3.7. Johnson & Johnson

                13.3.7.1. Company Overview

                13.3.7.2. Product Portfolio

                13.3.7.3. SWOT Analysis

                13.3.7.4. Strategic Overview

            13.3.8. Mallinckrodt Pharmaceuticals

                13.3.8.1. Company Overview

                13.3.8.2. Product Portfolio

                13.3.8.3. SWOT Analysis

                13.3.8.4. Strategic Overview

            13.3.9. Abbott Laboratories

                13.3.9.1. Company Overview

                13.3.9.2. Product Portfolio

                13.3.9.3. SWOT Analysis

                13.3.9.4. Strategic Overview

            13.3.10. GSK plc

                13.3.10.1. Company Overview

                13.3.10.2. Product Portfolio

                13.3.10.3. SWOT Analysis

                13.3.10.4. Strategic Overview

    List of Tables

    Table 01: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 02: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

    Table 03: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031

    Table 04: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031

    Table 05: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 06: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 07: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 08: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 09: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

    Table 10: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031

    Table 11: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031

    Table 12: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 13: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 14: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 15: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

    Table 16: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031

    Table 17: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031

    Table 18: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 19: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: North America Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: North America Diverticular Treatment Market Value Share, by Type, 2022

    Figure 03: North America Diverticular Treatment Market Value Share, by Treatment, 2022

    Figure 04: North America Diverticular Treatment Market Value Share, by Route of Administration, 2022

    Figure 05: North America Diverticular Treatment Market Value Share, by Distribution Channel, 2022

    Figure 06: North America Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031

    Figure 07: North America Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031

    Figure 08: North America Diverticular Treatment Market (US$ Mn), by Diverticulosis, 2017-2031

    Figure 09: North America Diverticular Treatment Market (US$ Mn), by Diverticulitis, 2017-2031

    Figure 10: North America Diverticular Treatment Market (US$ Mn), by Diverticular Hemorrhage, 2017-2031

    Figure 11: North America Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

    Figure 12: North America Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

    Figure 13: North America Diverticular Treatment Market (US$ Mn), by Medication, 2017-2031

    Figure 14: North America Diverticular Treatment Market (US$ Mn), by Nutritional Supplements, 2017-2031

    Figure 15: North America Diverticular Treatment Market (US$ Mn), by Probiotics, 2017-2031

    Figure 16: North America Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 17: North America Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 18: North America Diverticular Treatment Market (US$ Mn), by Oral, 2017-2031

    Figure 19: North America Diverticular Treatment Market (US$ Mn), by Parenteral, 2017-2031

    Figure 20: North America Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 21: North America Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 22: North America Diverticular Treatment Market (US$ Mn), by Hospital Pharmacies, 2017-2031

    Figure 23: North America Diverticular Treatment Market (US$ Mn), by Retail Pharmacies, 2017-2031

    Figure 24: North America Diverticular Treatment Market (US$ Mn), by Online Pharmacies, 2017-2031

    Figure 25: North America Diverticular Treatment Market Value Share Analysis, by Country, 2022 and 2031

    Figure 26: North America Diverticular Treatment Market Attractiveness Analysis, by Country, 2023-2031

    Figure 27: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031

    Figure 28: U.S. Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031

    Figure 29: U.S. Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031

    Figure 30: U.S. Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

    Figure 31: U.S. Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

    Figure 32: U.S. Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 33: U.S. Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 34: U.S. Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 35: U.S. Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 36: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031

    Figure 37: Canada Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031

    Figure 38: Canada Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031

    Figure 39: Canada Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

    Figure 40: Canada Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

    Figure 41: Canada Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 42: Canada Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 43: Canada Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 44: Canada Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 45: North America Diverticular Treatment Market Share, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved